Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

Summary by Rutland Herald
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 16, 2026-

2 Articles

Rutland HeraldRutland Herald
Center

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 16, 2026-

Read Full Article
Clinical Trials ArenaClinical Trials Arena

Mirum concludes Phase III EXPAND trial enrolment for Livmarli

Mirum Pharmaceuticals has completed enrolment in the Phase III EXPAND study assessing Livmarli in rare cholestatic liver diseases.The post Mirum concludes Phase III EXPAND trial enrolment for Livmarli appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Rutland Herald broke the news in on Monday, March 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Foster City icon

Foster City

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal